NCT02886702

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 855 (actual)
• Sponsor: Fougera Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Tazarotene Cream 0.05%	Tazarotene Cream 0.05% to cover only the lesions with a thin film.
DRUG	TAZORAC® (tazarotene) Cream 0.05%	TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
DRUG	Placebo	Placebo (vehicle of the test product) to cover only the lesions with a thin film.

Timeline

• Start date: 2016-09-19
• Primary completion: 2017-08-02
• Completion: 2017-08-02
• First posted: 2016-09-01
• Last updated: 2018-08-29
• Results posted: 2018-08-29

Locations

30 sites across 1 country: United States